Cargando…
Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis
Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5 (C5), thereby inhibiting its cleavage. On the other...
Autores principales: | Lortholary, Olivier, El-Sissy, Carine, Leporrier, Jérémie, Sze Wah Wong, Sarah, Dannaoui, Eric, Fremeaux-Bacchi, Véronique, Aimanianda, Vishukumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099467/ https://www.ncbi.nlm.nih.gov/pubmed/37065989 http://dx.doi.org/10.1093/ofid/ofad159 |
Ejemplares similares
-
Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012) -
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013) -
Host Soluble Mediators: Defying the Immunological Inertness of Aspergillus fumigatus Conidia
por: Wong, Sarah Sze Wah, et al.
Publicado: (2017) -
Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013) -
Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)